MX337169B - Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos. - Google Patents

Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.

Info

Publication number
MX337169B
MX337169B MX2013011071A MX2013011071A MX337169B MX 337169 B MX337169 B MX 337169B MX 2013011071 A MX2013011071 A MX 2013011071A MX 2013011071 A MX2013011071 A MX 2013011071A MX 337169 B MX337169 B MX 337169B
Authority
MX
Mexico
Prior art keywords
methods
compositions
same
compounds
isoindoline derivatives
Prior art date
Application number
MX2013011071A
Other languages
English (en)
Inventor
George W Muller
How-Wah Man
Alexander Ruchelman
Ehab M Khalil
Roger Shen-Chu
Weihong Zhang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX337169B publication Critical patent/MX337169B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)

Abstract

Se proporcionan compuestos de 4´-arilmetoxi isoindolina, y sales, solvatos, clatratos, estereoisómeros y profármacos farmacéuticamente aceptables de los mismos. Se describen los métodos de uso, y las composiciones farmacéuticas de estos compuestos. Los compuestos son derivados de hidroxi talidomida activa contra el cáncer.
MX2013011071A 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos. MX337169B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30361810P 2010-02-11 2010-02-11
PCT/US2011/024269 WO2011100380A1 (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Publications (1)

Publication Number Publication Date
MX337169B true MX337169B (es) 2016-02-16

Family

ID=43708752

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013011071A MX337169B (es) 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
MX2016001880A MX367522B (es) 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos.
MX2012009237A MX2012009237A (es) 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016001880A MX367522B (es) 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos.
MX2012009237A MX2012009237A (es) 2010-02-11 2011-02-10 Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.

Country Status (33)

Country Link
US (8) US8518972B2 (es)
EP (6) EP4289838A3 (es)
JP (5) JP2013519675A (es)
KR (2) KR101931468B1 (es)
CN (2) CN102822165B (es)
AR (1) AR081058A1 (es)
AU (1) AU2011215877C1 (es)
CA (1) CA2787823C (es)
CO (1) CO6571916A2 (es)
CR (1) CR20120414A (es)
CY (3) CY1119177T1 (es)
DK (3) DK3202461T3 (es)
EC (1) ECSP12012098A (es)
ES (5) ES2713482T3 (es)
HR (3) HRP20171078T1 (es)
HU (3) HUE042011T2 (es)
IL (2) IL220992A (es)
LT (3) LT2536706T (es)
ME (2) ME02766B (es)
MX (3) MX337169B (es)
NI (1) NI201200132A (es)
NZ (3) NZ601289A (es)
PH (2) PH12012501607A1 (es)
PL (3) PL3202460T3 (es)
PT (3) PT3202460T (es)
RS (3) RS56232B1 (es)
RU (1) RU2567753C2 (es)
SG (3) SG10202012179RA (es)
SI (3) SI3202460T1 (es)
SM (3) SMT201900420T1 (es)
TR (1) TR201903027T4 (es)
UA (2) UA115220C2 (es)
WO (1) WO2011100380A1 (es)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
EP2702410A2 (en) 2011-04-29 2014-03-05 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX358517B (es) 2012-06-29 2018-08-24 Celgene Corp Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
EA029485B1 (ru) 2012-08-09 2018-04-30 Селджин Корпорейшн Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
EP3741372A1 (en) * 2012-08-09 2020-11-25 Celgene Corporation (s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases
US20150038511A1 (en) * 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) * 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
BR112015002183A2 (pt) * 2012-08-09 2017-07-04 Celgene Corp processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014039960A1 (en) * 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MX386337B (es) 2013-12-06 2025-03-18 Celgene Corp Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células b grandes, mieloma múltiple, y cánceres mieloides.
MX387318B (es) * 2014-04-14 2025-03-18 Arvinas Operations Inc Moduladores de la proteólisis basados en imida y métodos de uso asociados.
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
ES2969532T3 (es) 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EP3925609B1 (en) 2014-08-22 2025-07-30 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
ES2812877T3 (es) * 2014-10-30 2021-03-18 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
CA2974367A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
EP3653628B1 (en) * 2015-07-21 2022-09-14 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016332236B2 (en) * 2015-09-29 2019-04-11 Kangpu Biopharmaceuticals, Ltd. Pharmaceutical composition and application thereof
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CA3020281A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123168C2 (uk) * 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3041840A1 (en) 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
EP3551185A4 (en) 2016-12-08 2021-07-14 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
AU2017376704B2 (en) 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP7679173B2 (ja) 2016-12-23 2025-05-19 アルビナス・オペレーションズ・インコーポレイテッド Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
WO2018140671A1 (en) 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP7534849B2 (ja) 2017-02-03 2024-08-15 セルジーン コーポレイション セレブロンに対する小分子の親和性の測定方法
US20200000776A1 (en) 2017-02-13 2020-01-02 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CN108929307A (zh) 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
SG11202000143PA (en) * 2017-07-10 2020-02-27 Celgene Corp Antiproliferative compounds and methods of use thereof
CN118638025A (zh) 2017-08-21 2024-09-13 细胞基因公司 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11299485B2 (en) 2018-01-25 2022-04-12 Fujimoto Co., Ltd. Thiophene derivative and use thereof
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
US11358952B2 (en) * 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
AU2019294414B2 (en) 2018-06-29 2023-06-29 F. Hoffmann-La Roche Ag Compounds
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
PL3820573T3 (pl) * 2018-07-10 2024-02-19 Novartis Ag Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
CN112689627B (zh) * 2018-09-07 2022-03-29 南京明德新药研发有限公司 三环取代哌啶二酮类化合物
EP3862348A4 (en) * 2018-09-30 2022-06-22 Shanghai Institute of Materia Medica, Chinese Academy of Sciences ISOINDOLINE COMPOUND, PROCESS OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
WO2020118098A1 (en) * 2018-12-05 2020-06-11 Vividion Therapeutics, Inc. Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
AU2019392231B2 (en) * 2018-12-06 2022-10-20 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
BR112021013435A2 (pt) * 2019-01-09 2021-10-19 Celgene Corporation Formas sólidas que compreendem (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila e sais do mesmo, e composições que compreendem e métodos de uso do mesmo
CN113597301A (zh) * 2019-01-09 2021-11-02 细胞基因公司 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法
EA202191903A1 (ru) 2019-01-09 2021-11-12 Селджин Корпорейшн Антипролиферативные соединения и вторые активные агенты для комбинированного применения
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
EP4048666A1 (en) * 2019-10-21 2022-08-31 Celgene Corporation Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
CN115697387A (zh) 2019-11-05 2023-02-03 细胞基因公司 抗bcma嵌合抗原受体的用途
BR112022007548A2 (pt) 2019-11-07 2022-07-12 Juno Therapeutics Inc Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
WO2021105335A1 (en) 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
AU2020392427B2 (en) 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
EP4069245A1 (en) 2019-12-02 2022-10-12 Celgene Corporation Therapy for the treatment of cancer
ES2986594T3 (es) * 2019-12-12 2024-11-12 Accutar Biotechnology Inc Nuevos derivados de cromano que tienen actividad de degradación del receptor de estrógeno y usos de los mismos
KR20220145325A (ko) * 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN114828959B (zh) 2019-12-18 2024-04-02 诺华股份有限公司 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CR20220353A (es) 2019-12-19 2022-10-20 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
CN115038694A (zh) * 2020-01-20 2022-09-09 康朴生物医药技术（上海）有限公司 一种异吲哚啉衍生物、其药物组合物及应用
US20230096517A1 (en) * 2020-02-25 2023-03-30 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN115803027A (zh) 2020-04-30 2023-03-14 百时美施贵宝公司 治疗细胞因子相关的不良事件的方法
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
IL299293A (en) 2020-06-25 2023-02-01 Celgene Corp Cancer treatment methods with combined treatments
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
CN115916768B (zh) * 2020-07-20 2024-12-24 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
CA3186919A1 (en) 2020-08-03 2022-02-10 Sylvain Cottens Low molecular weight protein degraders and their applications
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
CA3191282A1 (en) 2020-09-11 2022-03-17 William Pierceall Combination therapy for cancer
JP2023541434A (ja) 2020-09-14 2023-10-02 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体の標的化分解のための化合物の結晶性形態
WO2022066580A1 (en) * 2020-09-23 2022-03-31 Kinnate Biopharma Inc. Raf degrading compounds
CN116234553A (zh) 2020-10-02 2023-06-06 新基公司 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途
EP4241278A2 (en) 2020-11-04 2023-09-13 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CN112174976A (zh) * 2020-11-19 2021-01-05 江西中医药大学 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
TW202241872A (zh) * 2021-01-05 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
CA3211149A1 (en) * 2021-03-31 2022-10-06 Phillip Martin Cowley Pharmaceutical compound
AU2022259683A1 (en) 2021-04-16 2023-10-19 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
CA3215410A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023025136A1 (zh) * 2021-08-27 2023-03-02 杭州格博生物医药有限公司 异吲哚啉酮化合物及其用途
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
CN118510766A (zh) 2022-01-19 2024-08-16 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4522183A2 (en) 2022-05-11 2025-03-19 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN115160211B (zh) * 2022-06-23 2023-11-03 温州大学 一种异吲哚啉酮类化合物的绿色合成方法
CN117285524A (zh) * 2022-06-24 2023-12-26 中国科学院上海药物研究所 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
TW202532072A (zh) 2023-12-08 2025-08-16 美商西建公司 治療多發性骨髓瘤之療法
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) * 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5149820A (en) * 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0664128A4 (en) * 1992-10-07 1997-12-17 Sumitomo Pharma PHARMACEUTICAL COMPOSITION USED TO INHIBIT THE PRODUCTION OF TUMOR NECROSIS FACTORS.
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE69717831T3 (de) 1996-07-24 2018-08-30 Celgene Corp. Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
KR20000057693A (ko) 1996-12-20 2000-09-25 다케다 야쿠힌 고교 가부시키가이샤 지효성 제제의 제조 방법
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CZ299253B6 (cs) * 1998-03-16 2008-05-28 Celgene Corporation Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
DE60117486T2 (de) 2000-08-23 2006-11-16 General Electric Co. Spritzgegossene Keramik-Metallhalogenidbogenröhre mit einem nicht-konischen Ende
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2672000C (en) 2002-05-17 2011-11-29 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
SG133603A1 (en) 2003-09-17 2007-07-30 Us Gov Health & Human Serv Thalidomide analogs as tnf-alpha modulators
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20120039065A (ko) 2003-12-02 2012-04-24 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0509019A (pt) 2004-03-22 2007-08-07 Celgene Corp métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06012278A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
CA2565447A1 (en) 2004-05-05 2005-12-01 Celgene Corporation Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
EP1778676B1 (en) * 2004-07-16 2010-08-25 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
ES2438725T3 (es) * 2004-09-03 2014-01-20 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
CN101098694A (zh) 2004-11-12 2008-01-02 细胞基因公司 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
CA2612612C (en) 2005-06-30 2014-03-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
MX2008002765A (es) * 2005-08-31 2008-04-07 Celgene Corp Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
RS51725B (sr) 2006-09-15 2011-10-31 Celgene Corporation Jedinjenja n-metilaminometil izoindola i kompozicije koje ih sadrže i upotreba istih
CA2665778A1 (en) 2006-10-19 2008-05-15 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
CN103641814A (zh) * 2007-03-20 2014-03-19 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
EP2640189A4 (en) 2010-11-18 2014-03-19 Deuteria Pharmaceuticals Inc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
MX358517B (es) 2012-06-29 2018-08-24 Celgene Corp Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
EA029485B1 (ru) 2012-08-09 2018-04-30 Селджин Корпорейшн Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
EP3741372A1 (en) 2012-08-09 2020-11-25 Celgene Corporation (s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
BR112015002183A2 (pt) 2012-08-09 2017-07-04 Celgene Corp processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014039960A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MX386337B (es) 2013-12-06 2025-03-18 Celgene Corp Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células b grandes, mieloma múltiple, y cánceres mieloides.
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2969532T3 (es) 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US20170242014A1 (en) 2014-10-13 2017-08-24 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
ES2812877T3 (es) 2014-10-30 2021-03-18 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
DK2536706T3 (en) 2017-08-14
ES2638517T3 (es) 2017-10-23
DK3202460T3 (da) 2019-07-29
MX367522B (es) 2019-08-26
NZ700054A (en) 2016-03-31
UA114856C2 (uk) 2017-08-10
US10189814B2 (en) 2019-01-29
RS58523B1 (sr) 2019-04-30
HRP20191312T1 (hr) 2019-10-18
IL248843B (en) 2019-12-31
SMT201700360T1 (it) 2017-09-07
ES2738776T3 (es) 2020-01-27
US20110196150A1 (en) 2011-08-11
US9309219B2 (en) 2016-04-12
WO2011100380A1 (en) 2011-08-18
US11414399B2 (en) 2022-08-16
SI3202460T1 (sl) 2019-10-30
JP2013519675A (ja) 2013-05-30
AU2011215877B2 (en) 2013-11-07
EP3202461A1 (en) 2017-08-09
SG183257A1 (en) 2012-09-27
JP2017031165A (ja) 2017-02-09
JP6270944B2 (ja) 2018-01-31
US20130324518A1 (en) 2013-12-05
LT3202461T (lt) 2019-04-25
ES2730763T3 (es) 2019-11-12
HUE042011T2 (hu) 2019-06-28
LT2536706T (lt) 2017-10-25
KR101812356B1 (ko) 2017-12-26
IL248843A0 (en) 2017-01-31
SI3202461T1 (sl) 2019-05-31
MX2012009237A (es) 2012-08-23
PT3202460T (pt) 2019-08-05
EP2536706B1 (en) 2017-06-14
ECSP12012098A (es) 2012-10-30
KR20180000338A (ko) 2018-01-02
CN104693193A (zh) 2015-06-10
ME03441B (me) 2020-01-20
IL220992A (en) 2016-11-30
EP3202460A1 (en) 2017-08-09
CY1119177T1 (el) 2018-02-14
US20180037567A1 (en) 2018-02-08
NZ601289A (en) 2014-10-31
EP3599236A1 (en) 2020-01-29
UA115220C2 (uk) 2017-10-10
LT3202460T (lt) 2019-10-10
CN102822165B (zh) 2015-02-25
AU2011215877A1 (en) 2012-08-16
US20160159768A1 (en) 2016-06-09
PH12014501082A1 (en) 2015-09-28
EP3106460A1 (en) 2016-12-21
CR20120414A (es) 2012-10-31
JP2016172746A (ja) 2016-09-29
PH12014501082B1 (en) 2015-09-28
RU2567753C2 (ru) 2015-11-10
HUE044652T2 (hu) 2019-11-28
CA2787823C (en) 2018-04-10
US8518972B2 (en) 2013-08-27
NI201200132A (es) 2013-04-22
US20190135780A1 (en) 2019-05-09
SG10202012179RA (en) 2021-01-28
ME02766B (me) 2018-01-20
HRP20190368T1 (hr) 2019-04-19
CY1121729T1 (el) 2020-07-31
CO6571916A2 (es) 2012-11-30
EP3202461B1 (en) 2018-12-26
RS59275B1 (sr) 2019-10-31
RS56232B1 (sr) 2017-11-30
PT3202461T (pt) 2019-03-19
PT2536706T (pt) 2017-07-20
AU2011215877C1 (en) 2017-01-19
US9828361B2 (en) 2017-11-28
NZ717149A (en) 2017-06-30
TR201903027T4 (tr) 2019-03-21
EP2536706A1 (en) 2012-12-26
KR20130010888A (ko) 2013-01-29
US20220411402A1 (en) 2022-12-29
EP3599236B1 (en) 2023-08-23
US10669257B2 (en) 2020-06-02
SMT201900155T1 (it) 2019-05-10
EP3106460B1 (en) 2019-04-10
DK3202461T3 (en) 2019-03-18
KR101931468B1 (ko) 2018-12-20
HRP20171078T1 (hr) 2017-10-06
SI2536706T1 (sl) 2017-10-30
EP4289838A2 (en) 2023-12-13
JP2017200944A (ja) 2017-11-09
PH12012501607A1 (en) 2012-10-22
CY1121858T1 (el) 2020-10-14
PL2536706T3 (pl) 2017-10-31
SG10201501062SA (en) 2015-04-29
US20160159772A1 (en) 2016-06-09
ES2713482T3 (es) 2019-05-22
HUE033009T2 (en) 2017-11-28
JP6215976B2 (ja) 2017-10-18
CN104693193B (zh) 2018-09-18
US20200231567A1 (en) 2020-07-23
JP2016106106A (ja) 2016-06-16
EP4289838A3 (en) 2024-03-13
ES2956743T3 (es) 2023-12-27
CA2787823A1 (en) 2011-08-18
RU2012138709A (ru) 2014-03-20
AR081058A1 (es) 2012-06-06
US9822094B2 (en) 2017-11-21
PL3202460T3 (pl) 2019-12-31
SMT201900420T1 (it) 2019-11-13
EP3202460B1 (en) 2019-06-12
PL3202461T3 (pl) 2019-07-31
CN102822165A (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
PH12014501082A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
MY180812A (en) 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
UA95975C2 (ru) N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MX2011011136A (es) Eteres diarilicos.
PH12015501523A1 (en) Formulations of 4-amino-2-(2, 6-dioxopiperidine-3-yl) isiondoline-1, 3-dione
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2010009268A (es) Compuestos que son inhibidores de erk.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MY157495A (en) 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
EA033689B9 (ru) Ингибиторы g12c kras
WO2012142520A3 (en) Unit dose form for oral administration
IN2012DN03182A (es)
MX347928B (es) Derivados de fenetilsulfona isoindolina y su uso.
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
WO2012033983A3 (en) Candesartan pharmaceutical compositions
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
HK1133884A (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
HK1148279A (en) 5-substituted isoindoline compounds
TN2011000038A1 (en) Nitrogenated derivatives of pancratistatin